Company intelligence / Profile preview

RSK Medical

Ontario, Canada

Ownership: Private
Development stage: Other

Overview

RSK Medical delivers Health Canada-approved and clinically validated devices, including Angiodroid ACDA, which uses CO₂ as a safe imaging agent to reduce contrast use and improve patient safety in angiography, especially for those with renal impairment or contrast allergies.

Therapeutic areas: NephrologyCardiovascular
Modalities: Device
Industry: Medical Imaging

Partnerships

AngioSafe, Inc. (nationwide distribution agreement for Angiodroid ACDA)

Beyond the preview

Go deeper on RSK Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSK Medical.

Explore the full profile